Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemotherapy in Advanced Lung Cancer
NCT03432598Phase 2Completed
- Sponsor
- BeiGene
- Start
- Aug 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by BeiGene. Started Aug 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03432598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432598.